The United States Chronic Thromboembolic Pulmonary Hypertension Registry: Protocol for a Prospective, Longitudinal Study.

CTEPH nonsurgical pulmonary embolism pulmonary hypertension registry surgical therapy treatment

Journal

JMIR research protocols
ISSN: 1929-0748
Titre abrégé: JMIR Res Protoc
Pays: Canada
ID NLM: 101599504

Informations de publication

Date de publication:
25 May 2021
Historique:
received: 02 11 2020
accepted: 13 04 2021
revised: 24 03 2021
pubmed: 14 4 2021
medline: 14 4 2021
entrez: 13 4 2021
Statut: epublish

Résumé

Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare sequela of acute pulmonary embolism that is treatable when recognized. Awareness of this disease has increased with recent advancements in therapeutic options, but delays in diagnosis remain common, and diagnostic and treatment guidelines are often not followed. Data gathered from international registries have improved our understanding of CTEPH, but these data may not be applicable to the US population owing to differences in demographics and medical practice patterns. The US CTEPH Registry (US-CTEPH-R) was developed to provide essential information to better understand the demographics, risk factors, evaluation, and treatment of CTEPH in the United States, as well as the short- and long-term outcomes of surgical and nonsurgical therapies in the modern treatment era. Thirty sites throughout the United States enrolled 750 subjects in this prospective, longitudinal, observational registry of patients newly diagnosed with CTEPH. Enrollment criteria included a mean pulmonary artery pressure ≥25 mmHg by right heart catheterization and radiologic confirmation of CTEPH by a multidisciplinary adjudication committee. Following enrollment, subjects were followed biannually until the conclusion of the study. Quality of life surveys were administered at enrollment and biannually, and all other testing was at the discretion of the treating clinician. Details regarding surgical therapy, balloon pulmonary angioplasty, and medical therapy were collected at enrollment and at follow-up, as well as information related to health care utilization and survival. Data from this registry will improve understanding of the demographics, risk factors, and treatment patterns of patients with CTEPH, and the longitudinal impact of therapies on quality of life, health care utilization, and survival. This manuscript details the methodology and design of the first large, prospective, longitudinal registry of patients with CTEPH in the United States. ClinicalTrials.gov NCT02429284; https://www.clinicaltrials.gov/ct2/show/NCT02429284. DERR1-10.2196/25397.

Sections du résumé

BACKGROUND BACKGROUND
Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare sequela of acute pulmonary embolism that is treatable when recognized. Awareness of this disease has increased with recent advancements in therapeutic options, but delays in diagnosis remain common, and diagnostic and treatment guidelines are often not followed. Data gathered from international registries have improved our understanding of CTEPH, but these data may not be applicable to the US population owing to differences in demographics and medical practice patterns.
OBJECTIVE OBJECTIVE
The US CTEPH Registry (US-CTEPH-R) was developed to provide essential information to better understand the demographics, risk factors, evaluation, and treatment of CTEPH in the United States, as well as the short- and long-term outcomes of surgical and nonsurgical therapies in the modern treatment era.
METHODS METHODS
Thirty sites throughout the United States enrolled 750 subjects in this prospective, longitudinal, observational registry of patients newly diagnosed with CTEPH. Enrollment criteria included a mean pulmonary artery pressure ≥25 mmHg by right heart catheterization and radiologic confirmation of CTEPH by a multidisciplinary adjudication committee. Following enrollment, subjects were followed biannually until the conclusion of the study. Quality of life surveys were administered at enrollment and biannually, and all other testing was at the discretion of the treating clinician. Details regarding surgical therapy, balloon pulmonary angioplasty, and medical therapy were collected at enrollment and at follow-up, as well as information related to health care utilization and survival.
RESULTS RESULTS
Data from this registry will improve understanding of the demographics, risk factors, and treatment patterns of patients with CTEPH, and the longitudinal impact of therapies on quality of life, health care utilization, and survival.
CONCLUSIONS CONCLUSIONS
This manuscript details the methodology and design of the first large, prospective, longitudinal registry of patients with CTEPH in the United States.
TRIAL REGISTRATION BACKGROUND
ClinicalTrials.gov NCT02429284; https://www.clinicaltrials.gov/ct2/show/NCT02429284.
INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID) UNASSIGNED
DERR1-10.2196/25397.

Identifiants

pubmed: 33848258
pii: v10i5e25397
doi: 10.2196/25397
pmc: PMC8188310
doi:

Banques de données

ClinicalTrials.gov
['NCT02429284']

Types de publication

Journal Article

Langues

eng

Pagination

e25397

Informations de copyright

©Kim M Kerr, C Greg Elliott, Raymond L Benza, Richard N Channick, Kelly M Chin, R Duane Davis, Sonia Jain, Andrea Z LaCroix, Michael M Madani, Vallerie V McLaughlin, Myung H Park, Victor F Tapson, William R Auger. Originally published in JMIR Research Protocols (https://www.researchprotocols.org), 25.05.2021.

Références

Eur Radiol. 2007 Jan;17(1):11-21
pubmed: 16838142
Eur Radiol. 2014 Jan;24(1):42-51
pubmed: 23982287
J Am Coll Cardiol. 2013 Dec 24;62(25 Suppl):D51-9
pubmed: 24355642
Eur Radiol. 1998;8(8):1376-90
pubmed: 9853219
Am J Respir Crit Care Med. 2012 Oct 15;186(8):790-6
pubmed: 22798320
Eur Respir J. 2019 Jan 24;53(1):
pubmed: 30545969
Am J Respir Crit Care Med. 2006 May 1;173(9):1023-30
pubmed: 16456139
J Am Coll Cardiol. 2018 May 29;71(21):2468-2486
pubmed: 29793636
Chest. 2010 Feb;137(2):376-87
pubmed: 19837821
Circulation. 2016 Mar 1;133(9):859-71
pubmed: 26826181
Eur Respir J. 2014 Apr;43(4):1106-13
pubmed: 24232702
Ann Intern Med. 1987 Aug;107(2):216-23
pubmed: 3605900
Eur Respir Rev. 2017 Mar 15;26(143):
pubmed: 28298387
J Am Coll Cardiol. 2013 Dec 24;62(25 Suppl):D92-9
pubmed: 24355646
Radiology. 1992 Feb;182(2):393-8
pubmed: 1732955
Ann Am Thorac Soc. 2016 Jul;13 Suppl 3:S222-39
pubmed: 27571004
Circulation. 2011 Nov 1;124(18):1973-81
pubmed: 21969018

Auteurs

Kim M Kerr (KM)

Division of Pulmonary, Critical Care & Sleep Medicine, University of California San Diego, La Jolla, CA, United States.

C Greg Elliott (CG)

Department of Medicine, Intermountain Medical Center, Murray, UT, United States.

Raymond L Benza (RL)

Division of Cardiovascular Medicine, Ohio State University, Columbus, OH, United States.

Richard N Channick (RN)

Division of Pulmonary and Critical Care Medicine, University of California Los Angeles, Los Angeles, CA, United States.

Kelly M Chin (KM)

Division of Pulmonary and Critical Care, University of Texas Southwestern, Dallas, TX, United States.

R Duane Davis (RD)

Thoracic and Cardiac Surgery, AdventHealth Transplant Institute, Orlando, FL, United States.

Sonia Jain (S)

Division of Biostatistics and Bioinformatics, University of California San Diego, La Jolla, CA, United States.

Andrea Z LaCroix (AZ)

Division of Epidemiology, University of California San Diego, La Jolla, CA, United States.

Michael M Madani (MM)

Division of Cardiovascular and Thoracic Surgery, University of California San Diego, La Jolla, CA, United States.

Vallerie V McLaughlin (VV)

Division of Cardiovascular Medicine, University of Michigan, Ann Arbor, MI, United States.

Myung H Park (MH)

Department of Cardiology, Virginia Mason Franciscan Health, Tacoma, WA, United States.

Victor F Tapson (VF)

Division of Pulmonary and Critical Care Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, United States.

William R Auger (WR)

Division of Cardiology, Temple University, Philadelphia, PA, United States.

Classifications MeSH